Evolving Concepts in the Management of Diabetes and Cardiorenal Metabolic Diseases

Evolving Concepts in the Management of Diabetes and Cardiorenal Metabolic Diseases

Disclosures: de Boer reports being a consultant to Astra Zeneca, Bayer and Boehringer Ingelheim.
July 07, 2021
5 min watch
Save

VIDEO: de Boer discusses impact of CKD on cardiometabolic disease

Disclosures: de Boer reports being a consultant to Astra Zeneca, Bayer and Boehringer Ingelheim.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

In this video perspective, Ian de Boer, MD, MS, discusses the connection between chronic kidney disease and cardiometabolic disease.

de Boer, a professor of medicine and associate director of the Kidney Research Institute at the University of Washington in Seattle, told Healio Nephrology that “CKD is common, complicating type 1 and type 2 diabetes and the cardiometabolic syndrome, and also markedly increases the risk of cardiovascular disease, including cardiac failure.”

Screening for CKD among patients with diabetes  “is absolutely important” to detect kidney damage early, de Boer said. “It is morbid, we do have treatments and screening can help us determine who will benefit from these treatments,” he said.